SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Azitra, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

John E. Kulesza
105 Progress Drive,
Wethersfield, CT, 06109
860-529-7919

Naz Zilkha
Dechert LLP, Three Bryant Park, 1095 Avenue of the Americas
New York, NY, 10036-6797
212-698-3599

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/06/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Young Pharmaceuticals, Inc.

2	Check the appropriate box if a member of a Group (See Instructions)	☐ (a) ☐ (b)
3	SEC use only	
4	Source of funds (See Instructions)	WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	☐
6	Citizenship or place of organization	CONNECTICUT
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power	316,300.00
	8 Shared Voting Power	0.00
	9 Sole Dispositive Power	316,300.00
	10 Shared Dispositive Power	0.00
11	Aggregate amount beneficially owned by each reporting person	316,300.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	☐
13	Percent of class represented by amount in Row (11)	5.22 %
14	Type of Reporting Person (See Instructions)	CO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Azitra, Inc.
(c)	Address of Issuer's Principal Executive Offices: 21 Business Park Drive, Branford, CONNECTICUT , 06405.
Item 1 Comment:	Information given in response to each item herein shall be deemed incorporated by reference in all other items, as applicable.
Item 2.	Identity and Background
(a)	The name of the reporting person is Young Pharmaceuticals, Inc. ("Young Pharmaceuticals" or the "Reporting Person").
(b)	The address of Young Pharmaceuticals is 105 Progress Drive, Wethersfield CT 06109.
(c)	Young Pharmaceuticals is a developer and marketer of dermatological and aesthetic skincare.
(d)	No Reporting Person, nor any person listed on Schedule A, has, during the last five years, been convicted in a

criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the past five years, no Reporting Person, nor any person listed on Schedule A, was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Young Pharmaceuticals is incorporated in the State of Connecticut. The citizenship of the persons listed on Schedule A is set forth therein. Set forth on Schedule A annexed hereto ("Schedule A") is the name and present principal occupation or employment, principal business address and citizenship of the executive officers and directors of Young Pharmaceuticals. To the best of the Reporting Person's knowledge, none of the persons listed on Schedule A beneficially owns any securities of the Issuer or is a party to any contract, agreement or understanding required to be disclosed herein.

Item 3. Source and Amount of Funds or Other Consideration

Young Pharmaceuticals purchased the shares of the Issuer's Common Stock using its working capital in open-market purchases. The aggregate purchase price of the 316,300 shares of Common Stock directly beneficially owned by Young Pharmaceuticals is approximately $343,977.15, excluding brokerage commissions. Of this amount, approximately $198,992.70 was paid for the shares acquired in the transactions listed in Item 5(c), and approximately $144,984.45 was paid for shares acquired before the 60-day period covered by that table.

Item 4. Purpose of Transaction

The Reporting Person purchased the Common Stock based on the Reporting Person's belief that the Common Stock, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, and the availability of Common Stock at prices that would make the purchase or sale of Common Stock desirable, the Reporting Person may endeavor to increase or decrease its position in the Issuer through, among other things, the purchase or sale of Common Stock on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable. The Reporting Person intends to engage in communications with the Issuer's Board of Directors (the "Board") and management team regarding opportunities to enhance stockholder value. The Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Person intends to review its investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to its investment in the Issuer as it deems appropriate including, without limitation, engaging in additional communications with management and the Board of Directors of the Issuer, engaging in discussions with stockholders of the Issuer or other third parties about the Issuer and the Reporting Person's investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, purchasing additional shares of Common Stock, selling some or all of its shares of Common Stock, engaging in short selling of or any hedging or similar transaction with respect to the Common Stock, including swaps and other derivative instruments, or changing its intention with respect to any and all matters referred to in Item 4.

Item 5. Interest in Securities of the Issuer

(a) The aggregate percentage of shares of Common Stock reported as beneficially owned by Young Pharmaceuticals has been determined in accordance with SEC rules and is based upon 6,060,435 shares of Common Stock outstanding, which is the total number of shares of Common Stock outstanding as reported in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 12, 2026. The applicable SEC rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include shares of Common Stock issuable upon the conversion or exercise of other securities that are immediately convertible or exercisable, or are convertible or exercisable within 60 days of the filing of this Report. (a) As of the closing of business on November 16, 2026, Young Pharmaceuticals is the beneficial owner of 316,300 shares of the Issuer's Common Stock, representing a beneficial ownership interest of approximately 5.22% of the outstanding shares of Common Stock.

(b) 1. Sole power to vote or direct vote: 316,300 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 316,300 4. Shared power to dispose or direct the disposition: 0

(c) The following table details the transactions, all of which were purchases on the open market, effected by Young Pharmaceuticals in the past 60 days:(1) Transaction Date Price Per Share Number of Shares 11/06/2026 $0.77 35,788 11/06/2026 $0.7464 212 11/05/2026 $0.759 50,000 11/04/2026 $0.82 42,480 11/03/2026 $0.78 7,520 10/30/2026 $0.6999 30,000 10/30/2026 $0.698 20,000 10/29/2026 $0.7372 10,000 10/28/2026 $0.8863 10,000 10/27/2026 $1.0699 10,000 10/05/2026 $1.3490 7,500 10/02/2026 $1.3160 5,000 10/01/2026 $1.4390 5,000 09/30/2026 $1.3690 5,000 (1) On October 26, 2026, the Issuer effected a 1-for-10 reverse stock split (the "Reverse Stock Split") of its issued and outstanding shares of Common Stock and began trading on a split-adjusted basis the same day. There was no change in par value. Shares numbers and price per share information presented in this table for transactions conducted prior to October 26, 2026 have been adjusted to present the effect of the Reverse Stock Split. In addition to the shares acquired in the transactions listed above, Young Pharmaceuticals holds 77,800 shares of Common Stock, stated on a post-Reverse Stock Split basis, acquired before the 60-day period covered by the table. These earlier

holdings, together with the 238,500 shares represented by the listed transactions on a post-Reverse Stock Split basis, comprise the 316,300 shares reported in Item 5(a) and on the cover page.

(d) Not applicable.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

There are no contracts, arrangements, understandings or relationships (legal or otherwise) between Young Pharmaceuticals and any other person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

Item 7. Material to be Filed as Exhibits.

Schedule A - Directors and Officers

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Young Pharmaceuticals, Inc.

Signature: /s/ John E. Kulesza
Name/Title: President
Date: 11/16/2026

Schedule A

Directors and Officers of Young Pharmaceuticals, Inc.

Name	Principal Occupation	Principal Business Address	Citizenship
John E. Kulesza	President and Director	105 Progress Drive Wethersfield CT 06109	United States of America
Peter Pekarek Kostka	Chief Financial Officer and Director	105 Progress Drive Wethersfield CT 06109	United States of America
Shylah Cyr	Secretary	105 Progress Drive Wethersfield CT 06109	United States of America